Landiolol
Code | Size | Price |
---|
TAR-T5028L-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T5028L-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T5028L-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Landiolol is used as a highly cardioselective ultra short-acting beta-blocker.
CAS:
133242-30-5
Formula:
C25H39N3O8
Molecular Weight:
509.6
Purity:
0.98
SMILES:
CC1(C)OCC(COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1
References
Xiao J, He P, Zou Q, Zhao Y, Xue Z, Deng X, Li S, Guo Q, Tao G, Yang T, Lang Z, He J, Wang X. Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Anesth. 2015 Mar;27(2):120-8. doi: 10.1016/j.jclinane.2014.07.003. Epub 2014 Nov 28. PubMed PMID: 25434501.
Kinugawa K, Nagai R, Inoue H, Atarashi H, Seino Y, Yamashita T, Shimizu W, Aiba T, Kitakaze M, Sakamoto A, Ikeda T, Imai Y, Daimon T, Fujino K, Nagano T, Okamura T, Hori M; J-Land Investigators. Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study. Adv Ther. 2014 Apr;31(4):426-39. doi: 10.1007/s12325-014-0111-2. Epub 2014 Mar 19. Erratum in: Adv Ther. 2014 May;31(5):577-8. PubMed PMID: 24643403; PubMed Central PMCID: PMC4003342.
Kunisawa T, Yamagishi A, Suno M, Nakade S, Higashi R, Kurosawa A, Sugawara A, Matsubara K, Iwasaki H. Target-controlled infusion and population pharmacokinetics of landiolol hydrochloride in gynecologic patients. J Anesth. 2015 Apr;29(2):198-205. doi: 10.1007/s00540-014-1908-5. Epub 2014 Sep 4. PubMed PMID: 25186494.
Okajima M, Takamura M, Taniguchi T. Landiolol, an ultra-short-acting ?1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis. World J Crit Care Med. 2015 Aug 4;4(3):251-7. doi: 10.5492/wjccm.v4.i3.251. eCollection 2015 Aug 4. PubMed PMID: 26261777; PubMed Central PMCID: PMC4524822.